Hong Kong-listed CanSino Biologics said in a filing to the stock exchange that data from clinical trials showed the Chinese military vaccine had a "good safety profile" and potential to prevent disease caused by the novel coronavirus.
CNBG, affiliated to the state-owned China National Pharmaceutical Group (Sinopharm), said earlier this month that another vaccine candidate produced by its Wuhan-based unit also triggered high-level antibodies safely in clinical trial participants based on preliminary results.
The vaccine has also received approval for human testing in Canada.
CanSino said Monday that China's Central Military Commission approved the use of the vaccine on June 25, for one year. It can not be expanded to a broader vaccination range without receiving a go-ahead from the Logistics Support Department, the biotech firm said.
According to researchers, the results of the clinical trial showed that the vaccination is safe and has no serious reaction.
More than half of 17 candidate vaccines identified by the World Health Organization (WHO) that are in clinical evaluation involve Chinese companies or institutes.
The Phase 1 and Phase 2 clinical trials showed the vaccine candidate has potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success can not be guaranteed, the company said.
No vaccine has been approved by any country for commercial use against the disease caused by coronavirus. Scientists all over the world are working days and nights to develop the vaccine for Covid-19.
The pandemic has killed more than 501,000 people worldwide, with over 10.14 million confirmed cases and more than 5.14 million recoveries, according to figures compiled by US-based Johns Hopkins University.